Product image of Mirabegron Eg (Mirabegron) supplied by GNH India

Mirabegron Eg

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Eg (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Eg, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the management of overactive bladder, reducing urinary urgency, frequency and urge urinary incontinence in adult patients by relaxing the detrusor muscle and increasing functional bladder capacity.

GNH India supplies Mirabegron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is used to treat conditions related to overactive bladder and urinary storage dysfunction.

  • Overactive bladder: reduces urgency, frequency and urge incontinence.
  • Urinary urgency: provides relief by increasing bladder capacity.
  • Urinary frequency: decreases daytime voiding episodes.
  • Urge urinary incontinence: helps control involuntary leakage.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors on detrusor smooth muscle, leading to relaxation of the bladder wall during the storage phase. This action increases functional bladder capacity and reduces involuntary contractions, thereby improving urinary storage symptoms associated with overactive bladder.

Side Effects

Common Side Effects

  • Hypertension: elevated blood pressure may occur.
  • Nasopharyngitis: mild upper respiratory tract infection.
  • Headache: occasional throbbing or tension headache.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.
  • Urinary tract infection: symptoms of infection may appear.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Tachycardia: rapid heart rate.
  • Severe hypertension: markedly high blood pressure.
  • Angioedema: swelling of face, lips or throat.
  • Myocardial infarction: rare heart attack events.
  • Anaphylaxis: severe allergic reaction.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Assess blood pressure: monitor for hypertension before and during treatment.
  • Review renal function: adjust use in patients with severe impairment.
  • Evaluate cardiovascular status: use cautiously in arrhythmias or heart disease.
  • Avoid in uncontrolled hypertension: contraindicated in markedly elevated pressure.
  • Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Mirabegron may interact with several drug classes; monitor accordingly.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine): may increase mirabegron exposure.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
  • Antihypertensive agents: may attenuate blood‑pressure‑lowering effect.
  • Nitrates: additive vasodilatory effect may cause hypotension.
  • Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor electrolytes and blood pressure.
  • Anticholinergic agents: may increase risk of urinary retention.

Frequently Asked Questions

Mirabegron Eg is prescribed for adults with overactive bladder, including symptoms such as urinary urgency, increased frequency, and urge urinary incontinence. It helps improve bladder storage capacity and reduces involuntary contractions.

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation relaxes the muscle during the filling phase, allowing the bladder to hold more urine and decreasing the frequency of unwanted contractions.

The specific dose of Mirabegron Eg is determined by the prescribing clinician based on the patient’s medical condition, response, and any concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mirabegron Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike anticholinergics, which block muscarinic receptors, Mirabegron activates β3‑adrenergic receptors, offering an alternative mechanism that may be better tolerated in patients who experience dry mouth or constipation with anticholinergics. Both classes aim to reduce overactive bladder symptoms but have distinct side‑effect profiles.

Mirabegron Eg should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

Mirabegron Eg is taken orally, usually as a whole tablet with or without food, according to the prescriber’s directions. Swallow the tablet whole; do not crush, split, or chew unless instructed otherwise.

Serious risks include significant hypertension, urinary retention, tachycardia, angioedema, myocardial infarction, and rare cases of anaphylaxis. Patients should seek immediate medical attention if they experience severe chest pain, rapid heartbeat, swelling of the face or throat, or inability to urinate.

Mirabegron Eg is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any excipients. Caution is also advised for individuals with significant cardiovascular disease, severe renal impairment, or those taking interacting medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT